![How to Find Low-Competition Keywords with Semrush [Super Easy]](https://static.semrush.com/blog/uploads/media/73/62/7362f16fb9e460b6d58ccc09b4a048b6/how-to-find-low-competition-keywords-sm.png)
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade
Equity markets recently dipped due to concerns of deteriorating macroeconomic conditions, with the latest trigger being President Trump's trade wars. The S&P 500 index's performance over the trailing-12-month period no longer looks quite as impressive as it did at the start of 2025 -- the equity index is down nearly 1.5% over this period. More importantly, the index is down a massive 13.8% so far this year.Some companies have performed much better, though. Summit Therapeutics (NASDAQ: SMMT) and Robinhood Markets (NASDAQ: HOOD) belong on that list. Both companies have crushed the market in the past year and remain excellent buy-and-hold options. Here is why Summit Therapeutics and Robinhood could deliver strong returns through the next decade.Summit Therapeutics is a clinical-stage biotech company with a market cap of $15.1 billion -- which is exceedingly rare for companies without a single product on the market. Last year, the drugmaker's shares skyrocketed after its leading candidate, ivonescimab, produced strong clinical results.Continue reading
Equity markets recently dipped due to concerns of deteriorating macroeconomic conditions, with the latest trigger being President Trump's trade wars. The S&P 500 index's performance over the trailing-12-month period no longer looks quite as impressive as it did at the start of 2025 -- the equity index is down nearly 1.5% over this period. More importantly, the index is down a massive 13.8% so far this year.
Some companies have performed much better, though. Summit Therapeutics (NASDAQ: SMMT) and Robinhood Markets (NASDAQ: HOOD) belong on that list. Both companies have crushed the market in the past year and remain excellent buy-and-hold options. Here is why Summit Therapeutics and Robinhood could deliver strong returns through the next decade.
Summit Therapeutics is a clinical-stage biotech company with a market cap of $15.1 billion -- which is exceedingly rare for companies without a single product on the market. Last year, the drugmaker's shares skyrocketed after its leading candidate, ivonescimab, produced strong clinical results.
